ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors.

The E2F and MYC transcription factors are critical regulators of cell proliferation and contribute to the development of human cancers. Here, we report on the identification of a novel E2F target gene, ATAD2, the predicted protein product of which contains both a bromodomain and an ATPase domain. The pRB-E2F pathway regulates ATAD2 expression, which is limiting for the entry into the S phase of the cell cycle. We show that ATAD2 binds the MYC oncogene and stimulates its transcriptional activity. ATAD2 maps to chromosome 8q24, 4.3 Mb distal to MYC, in a region that is frequently found amplified in cancer. Consistent with this, we show that ATAD2 expression is high in several human tumors and that the expression levels correlate with clinical outcome of breast cancer patients. We suggest that ATAD2 links the E2F and MYC pathways and contributes to the development of aggressive cancer through the enhancement of MYC-dependent transcription.

[1]  C. Tepper,et al.  Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. , 2009, Cancer research.

[2]  A. Revenko,et al.  ANCCA, an estrogen-regulated AAA+ ATPase coactivator for ERα, is required for coregulator occupancy and chromatin modification , 2007, Proceedings of the National Academy of Sciences.

[3]  M. Eilers,et al.  Transcriptional regulation and transformation by Myc proteins , 2005, Nature Reviews Molecular Cell Biology.

[4]  P. Carter,et al.  Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer , 2004, Oncogene.

[5]  Bradley P. Coe,et al.  Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer , 2004, Genes, chromosomes & cancer.

[6]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[7]  J. Sebat,et al.  Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. , 2003, Genome research.

[8]  M. J. van de Vijver,et al.  Association of C‐MYC amplification with progression from the in situ to the invasive stage in C‐MYC‐amplified breast carcinomas , 2003, The Journal of pathology.

[9]  D. Livingston,et al.  MYC recruits the TIP60 histone acetyltransferase complex to chromatin , 2003, EMBO reports.

[10]  B. Lüscher,et al.  Stimulation of c‐MYC transcriptional activity and acetylation by recruitment of the cofactor CBP , 2003, EMBO reports.

[11]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[12]  R. Salunga,et al.  Gene expression profiles of human breast cancer progression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Michael T. McManus,et al.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference , 2003, Nature Genetics.

[14]  K. Furge,et al.  Identification of frequent cytogenetic aberrations in hepatocellular carcinoma using gene-expression microarray data , 2002, Genome Biology.

[15]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Tattersall,et al.  Parvovirus Initiator Protein NS1 and RPA Coordinate Replication Fork Progression in a Reconstituted DNA Replication System , 2002, Journal of Virology.

[17]  P. Grant,et al.  Recruitment of Gcn5-containing Complexes during c-Myc-dependent Gene Activation , 2002, The Journal of Biological Chemistry.

[18]  Alejandro A Schäffer,et al.  Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression , 2002, Genes, chromosomes & cancer.

[19]  D. Botstein,et al.  Gene expression patterns in human liver cancers. , 2002, Molecular biology of the cell.

[20]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[21]  Ming-Ming Zhou,et al.  Bromodomain: an acetyl‐lysine binding domain , 2002, FEBS letters.

[22]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[23]  T. Poggio,et al.  Multiclass cancer diagnosis using tumor gene expression signatures , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Fernandez,et al.  Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. , 2001, Genes & development.

[25]  M. Schwartz,et al.  Integrins and cell proliferation: regulation of cyclin-dependent kinases via cytoplasmic signaling pathways. , 2001, Journal of cell science.

[26]  S. Berger,et al.  Structure and function of bromodomains in chromatin-regulating complexes. , 2001, Gene.

[27]  R. Kuick,et al.  Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. , 2000, Cancer research.

[28]  D. Beach,et al.  p16INK4A and p19ARF act in overlapping pathways in cellular immortalization , 2000, Nature Cell Biology.

[29]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[30]  M. Cole,et al.  The Essential Cofactor TRRAP Recruits the Histone Acetyltransferase hGCN5 to c-Myc , 2000, Molecular and Cellular Biology.

[31]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[32]  K. Helin,et al.  CDC25A Phosphatase Is a Target of E2F and Is Required for Efficient E2F-Induced S Phase , 1999, Molecular and Cellular Biology.

[33]  Lei Zeng,et al.  Structure and ligand of a histone acetyltransferase bromodomain , 1999, Nature.

[34]  E. Prochownik,et al.  MYC oncogenes and human neoplastic disease , 1999, Oncogene.

[35]  S. G. Cheng,et al.  c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function , 1999, Nature Genetics.

[36]  E V Koonin,et al.  AAA+: A class of chaperone-like ATPases associated with the assembly, operation, and disassembly of protein complexes. , 1999, Genome research.

[37]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[38]  H. Friess,et al.  Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. , 1997, Cancer research.

[39]  K. Helin,et al.  Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. , 1993, Genes & development.

[40]  J. Nickerson,et al.  Core filaments of the nuclear matrix , 1990, The Journal of cell biology.